Drug Trial Radar · NCT01421342
VA Augmentation and Switching Treatments for Improving Depression Outcomes
Last checked: Nov 19, 2026Latest source record: May 29, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,522
Actual
Start
Dec 2012
Primary completion
Aug 2015
Study completion Jun 2016
Sponsor
- Lead sponsor
- VA Office of Research and DevelopmentFederal agency
- Sponsor type
- Federal agency
- First posted
- Aug 22, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overall purpose is to determine research based 'next-steps' for outpatients with major depressive disorder who have not had satisfactory outcomes to standard 'first-step' treatments. The primary objective is to compare the acute (up to 12 weeks) treatment effectiveness of augmenting an antidepressant with aripiprazole or with bupropion-slow release (SR) vs. switching treatment to bupropion-SR monotherapy on symptom remission in Veterans with Major Depressive Disorder (MDD) who have not achieved optimal response after an adequate trial on antidepressant (a selective serotonin reuptake inhibitor \[SSRI\] or serotonin and norepinephrine reuptake inhibitor \[SNRI\] or mirtazapine) monotherapy. The secondary objectives are to compare the acute (up to 12 weeks) and long term (up to 36 weeks) efficacy, safety, effects on functioning, suicidality, quality of life, anxiety and other associated symptoms, costs and cost-effectiveness of each of the three treatments.
Conditions
- Major Depressive Disorder
Interventions
Switching: Bupropion-SRDrug
Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.
Augmenting: Antidepressant + Bupropion-SRDrug
Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment, or adjust depending on response or side effect profile for up to 36 weeks. And Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.
Augmenting: Antidepressant + AripiprazoleDrug
Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment or adjust depending on response or side effect profile for up to 36 weeks. And Aripiprazole (Dose: 2 mg - 15 mg taken orally once per day for up to 36 weeks): Initiating with aripiprazole dose of 2 mg for one week, then increasing dose per protocol up to 15 mg, maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Protocol Remission of Symptoms of Major Depressive DisorderTime frame: During acute phase (12 weeks)
Locations
35 sites in 1 country. Site status is shown where the registry gives one.
Tuscaloosa VA Medical Center, Tuscaloosa, AL
Tuscaloosa, Alabama
Phoenix VA Health Care System, Phoenix, AZ
Phoenix, Arizona
Southern Arizona VA Health Care System, Tucson
Tucson, Arizona
VA Loma Linda Healthcare System, Loma Linda, CA
Loma Linda, California
VA Long Beach Healthcare System, Long Beach, CA
Long Beach, California
VA Palo Alto Health Care System, Palo Alto, CA
Palo Alto, California
VA San Diego Healthcare System, San Diego, CA
San Diego, California
San Francisco VA Medical Center, San Francisco, CA
San Francisco, California
VA Eastern Colorado Health Care System, Denver, CO
Denver, Colorado
VA Connecticut Healthcare System West Haven Campus, West Haven, CT
West Haven, Connecticut
Washington DC VA Medical Center, Washington, DC
Washington D.C., District of Columbia
Miami VA Healthcare System, Miami, FL
Miami, Florida
James A. Haley Veterans' Hospital, Tampa, FL
Tampa, Florida
Atlanta VA Medical and Rehab Center, Decatur, GA
Decatur, Georgia
Edward Hines Jr. VA Hospital, Hines, IL
Hines, Illinois
Richard L. Roudebush VA Medical Center, Indianapolis, IN
Indianapolis, Indiana
Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
Baltimore, Maryland
Minneapolis VA Health Care System, Minneapolis, MN
Minneapolis, Minnesota
Kansas City VA Medical Center, Kansas City, MO
Kansas City, Missouri
St. Louis VA Medical Center John Cochran Division, St. Louis, MO
St Louis, Missouri
Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE
Omaha, Nebraska
New Mexico VA Health Care System, Albuquerque, NM
Albuquerque, New Mexico
Asheville VA Medical Center, Asheville, NC
Asheville, North Carolina
Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC
Salisbury, North Carolina
Cincinnati VA Medical Center, Cincinnati, OH
Cincinnati, Ohio
Louis Stokes VA Medical Center, Cleveland, OH
Cleveland, Ohio
Philadelphia VA Medical Center, Philadelphia, PA
Philadelphia, Pennsylvania
VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA
Pittsburgh, Pennsylvania
Memphis VA Medical Center, Memphis, TN
Memphis, Tennessee
Central Texas Veterans Health Care System, Temple, TX
Temple, Texas
Salem VA Medical Center, Salem, VA
Salem, Virginia
VA Puget Sound Health Care System American Lake Division, Tacoma, WA
Tacoma, Washington
Clarksburg Louis A. Johnson VA Medical Center, Clarksburg, WV
Clarksburg, West Virginia
William S. Middleton Memorial Veterans Hospital, Madison, WI
Madison, Wisconsin
Clement J. Zablocki VA Medical Center, Milwaukee, WI
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.